ITGB2 and non-small cell lung carcinoma: CD8 + T cells was one of the common prevalent T cells subtypes[33] and the triple-therapy of niraparib, RT, and anti-PD-1 could improve the antitumor immunity by enhancing cytotoxic CD8 + T cells in the TME.[20] In NSCLC, the patients with high level of CD8 + T cells exhibited better prognosis.[34] Thus, ITGB2 might be a CD8 + T cells infiltration marker in lung cancer patients.